Roche Wooing Biomarin or Is It Floating Another Trial Balloon?
By Marie Powers
Thursday, September 19, 2013
Shares of Biomarin Pharmaceutical Inc. topped $80 Thursday morning, one day after hitting a previous 52-week high. Although the stock (NASDAQ:BMRN) lost some lift late in the day, closing up 90 cents at $78.39, the uptick still pushed the company’s market cap to $11 billion.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.